ARCUTIS BIOTHERAPEUTICS, INC. Cost of Revenue
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Cost of Revenue of $10.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $10.94M, a 46.01% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $9.78M, a 10.80% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $11.69M, a 69.27% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $8.69M, a 57.82% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. cost of goods and services sold for fiscal 2025 was $36.70M, a 91.84% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. cost of goods and services sold for fiscal 2024 was $19.13M, a 283.56% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. cost of goods and services sold for fiscal 2023 was $4.99M, a 561.41% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. cost of goods and services sold for fiscal 2022 was $754.00K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.94M 10-Q · filed 2026-08-05 | $20.72M 10-Q · filed 2026-08-05 | $32.41M derived: sum of 3 quarters · filed 2026-08-05 | $41.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $9.78M 10-Q · filed 2026-05-06 | $21.47M derived: sum of 2 quarters · filed 2026-05-06 | $30.16M derived: sum of 3 quarters · filed 2026-05-06 | $37.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $11.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $20.37M derived: sum of 2 quarters · filed 2026-02-25 | $27.86M derived: sum of 3 quarters · filed 2026-08-05 | $36.70M 10-K · filed 2026-02-25 |
| 2025-09-30 | $8.69M 10-Q · filed 2025-10-28 | $16.18M derived: sum of 2 quarters · filed 2026-08-05 | $25.01M 10-Q · filed 2025-10-28 | $31.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.49M 10-Q · filed 2026-08-05 | $16.32M 10-Q · filed 2026-08-05 | $23.23M derived: sum of 3 quarters · filed 2026-08-05 | $28.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $8.83M 10-Q · filed 2026-05-06 | $15.73M derived: sum of 2 quarters · filed 2026-05-06 | $21.24M derived: sum of 3 quarters · filed 2026-05-06 | $24.70M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.41M derived: sum of 2 quarters · filed 2026-02-25 | $15.87M derived: sum of 3 quarters · filed 2026-02-25 | $19.13M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.50M 10-Q · filed 2025-10-28 | $8.97M derived: sum of 2 quarters · filed 2025-10-28 | $12.22M 10-Q · filed 2025-10-28 | $14.47M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.46M 10-Q · filed 2025-08-06 | $6.72M 10-Q · filed 2025-08-06 | $8.97M derived: sum of 3 quarters · filed 2026-02-25 | $10.15M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.26M 10-Q · filed 2025-05-06 | $5.50M derived: sum of 2 quarters · filed 2026-02-25 | $6.68M derived: sum of 3 quarters · filed 2026-02-25 | $7.46M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.43M derived: sum of 2 quarters · filed 2026-02-25 | $4.20M derived: sum of 3 quarters · filed 2026-02-25 | $4.99M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.18M 10-Q · filed 2024-11-06 | $1.96M derived: sum of 2 quarters · filed 2024-11-06 | $2.74M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $776.00K 10-Q · filed 2024-08-14 | $1.56M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $783.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $754.00K 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |